Praxis Precision Medicines (PRAX) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 76.9% versus a gain of 7.0%. Over five years, PRAX leads with a +19.5% price change compared with +18.2% for RDY. Dr. Reddy's Laboratories is the larger company by market cap ($12.41 billion vs $8.40 billion), about 1.5 times the size.
Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Praxis Precision Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | RDY |
|---|---|---|
| Share price | $300.43 | $14.89 |
| Market cap | $8.40B | $12.41B |
| 1-day change | -3.37% | +0.40% |
| YTD return | +1.93% | +6.05% |
| 1-year return | +76.93% | +7.05% |
| 5-year return | +19.50% | +18.19% |
| P/E ratio (TTM) | — | 41.36 |
| Forward P/E | — | 22.47 |
| EPS (TTM) | $-12.82 | $0.36 |
| Dividend yield | 0.00% | 53.73% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $0 | $3.81B |
| Revenue growth (YoY) | -100.00% | +13.76% |
| Net income (latest FY) | $-303.27M | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | — | 22.09% |
| Net margin | — | 17.40% |
| 52-week high | $392.70 | $15.67 |
| 52-week low | $167.32 | $11.36 |
| Distance from 52-week high | -23.50% | -4.98% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +124.49% | +0.20% |
| Average volume | 479.87K | 2.85M |
| Shares outstanding | 27.95M | 833.66M |
| Employees | 168 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed RDY by 69.9 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).
- Dr. Reddy's Laboratories grew revenue faster in its latest fiscal year (+13.76% vs -100.00%).
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
PRAX vs RDY FAQ
Which is bigger, Praxis Precision Medicines or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $12.41B compared with $8.40B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, PRAX or RDY?
PRAX returned +76.93% over the past 12 months, compared with +7.05% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Praxis Precision Medicines or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Praxis Precision Medicines does not currently pay a regular dividend.
Are Praxis Precision Medicines and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.